Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Notes Payables (2016 - 2017)

Bio-Techne has reported Notes Payables over the past 4 years, most recently at $14.6 million for Q1 2017.

  • Quarterly results put Notes Payables at $14.6 million for Q1 2017, up 282.83% from a year ago — trailing twelve months through Mar 2017 was $14.6 million (up 282.83% YoY), and the annual figure for FY2016 was $3.8 million, down 6.59%.
  • Notes Payables for Q1 2017 was $14.6 million at Bio-Techne, up from $3.6 million in the prior quarter.
  • Over the last five years, Notes Payables for TECH hit a ceiling of $14.6 million in Q1 2017 and a floor of $3.0 million in Q1 2015.
  • Median Notes Payables over the past 4 years was $3.8 million (2015), compared with a mean of $5.2 million.
  • Biggest five-year swings in Notes Payables: tumbled 36.67% in 2015 and later soared 282.83% in 2017.
  • Bio-Techne's Notes Payables stood at $6.0 million in 2014, then tumbled by 36.67% to $3.8 million in 2015, then dropped by 5.12% to $3.6 million in 2016, then soared by 305.51% to $14.6 million in 2017.
  • The last three reported values for Notes Payables were $14.6 million (Q1 2017), $3.6 million (Q4 2016), and $3.7 million (Q3 2016) per Business Quant data.